NASDAQ
Damora Therapeutics, Inc. - Ordinary Shares (DMRA)
♥ 408 Thanks from members
Damora Therapeutics (DMRA) exhibits strong momentum, driven by its transition from Galecto, clinical programs targeting mutant CALR myeloproliferative neoplasms, and favorable analyst actions, despite lacking trailing revenue and showing high R&D-stage net losses.